Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Asia Pacific Antibiotics Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 21
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Antibiotics Market 23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Antibiotics Market 27
Figure 11. Investment Opportunity Analysis 31
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Antibiotics Market 34
Figure 13. Breakdown of Asia Pacific Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%) 39
Figure 15. Asia Pacific Antibiotics Market: Cephalosporin, 2019-2030, $ mn 40
Figure 16. Asia Pacific Antibiotics Market: Penicillin, 2019-2030, $ mn 41
Figure 17. Asia Pacific Antibiotics Market: Macrolides, 2019-2030, $ mn 42
Figure 18. Asia Pacific Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn 43
Figure 19. Asia Pacific Antibiotics Market: Quinolones, 2019-2030, $ mn 44
Figure 20. Asia Pacific Antibiotics Market: Monobactam, 2019-2030, $ mn 45
Figure 21. Asia Pacific Antibiotics Market: Aminoglycosides, 2019-2030, $ mn 46
Figure 22. Asia Pacific Antibiotics Market: Carbapenem, 2019-2030, $ mn 47
Figure 23. Asia Pacific Antibiotics Market: Other Drug Classes, 2019-2030, $ mn 48
Figure 24. Breakdown of Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50
Figure 25. Asia Pacific Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%) 50
Figure 26. Asia Pacific Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn 51
Figure 27. Asia Pacific Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn 52
Figure 28. Asia Pacific Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn 53
Figure 29. Asia Pacific Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn 54
Figure 30. Asia Pacific Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn 55
Figure 31. Asia Pacific Antibiotics Market: Other Mechanisms, 2019-2030, $ mn 56
Figure 32. Breakdown of Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58
Figure 33. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%) 58
Figure 34. Asia Pacific Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn 59
Figure 35. Asia Pacific Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn 60
Figure 36. Asia Pacific Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn 61
Figure 37. Breakdown of Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63
Figure 38. Asia Pacific Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%) 63
Figure 39. Asia Pacific Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn 64
Figure 40. Asia Pacific Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn 65
Figure 41. Breakdown of Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 67
Figure 42. Asia Pacific Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%) 67
Figure 43. Asia Pacific Antibiotics Market: Oral Administration, 2019-2030, $ mn 68
Figure 44. Asia Pacific Antibiotics Market: Intravenous Administration, 2019-2030, $ mn 69
Figure 45. Asia Pacific Antibiotics Market: Other Administration Routes, 2019-2030, $ mn 70
Figure 46. Breakdown of Asia Pacific Antibiotics Market by Drug Type, 2019-2030, % of Revenue 71
Figure 47. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%) 72
Figure 48. Asia Pacific Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn 73
Figure 49. Asia Pacific Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn 74
Figure 50. Breakdown of APAC Antibiotics Market by Country, 2019 and 2030, % of Revenue 76
Figure 51. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 77
Figure 52. Antibiotics Market in Japan, 2019-2030, $ bn 79
Figure 53. Antibiotics Market in China, 2019-2030, $ bn 81
Figure 54. Antibiotics Market in Australia, 2019-2030, $ bn 83
Figure 55. Antibiotics Market in India, 2019-2030, $ bn 85
Figure 56. Antibiotics Market in South Korea, 2019-2030, $ bn 87
Figure 57. Antibiotics Market in Rest of APAC, 2019-2030, $ bn 89
Figure 58. Growth Stage of Asia Pacific Antibiotics Industry over the Forecast Period 91
Asia Pacific antibiotics market will grow by 4.1% annually with a total addressable market cap of $253.1 billion over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic. Highlighted with 32 tables and 58 figures, this 121-page report “Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country. Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cephalosporin • Penicillin • Macrolides • Fluoroquinolones • Quinolones • Monobactam • Aminoglycosides • Carbapenem • Other Drug Classes Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Intravenous Administration • Other Administration Routes Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More